Back

The impact of serum amolyoid A on long term mortality (12 years) in patients with carotid atherosclerosis.

29 August 2017 (14:36 - 14:54)
Organised by:
Congress Presentation Part of: Integration of old and new prognostic biomarkers in patients with cardiovascular disease Biomarkers ESC Premium Access ESC Congress 2017

About the speaker

Photo
Associate Professor Matthias Hoke

Medical University of Vienna, Vienna (Austria)

4 More presentations in this session

Presentation thumbnail
State of the art: integration of old and new prognostic biomarkers in patients with cardiovascular disease
Professor M. Kavousi (Rotterdam, NL)
Presentation thumbnail
Iron deficiency independently and strongly predicts adverse outcome in patients with acute coronary syndrome - first report on the prospective relevance of iron deficiency
Doctor S. Schaefer (Hamburg, DE)
Abstract Slides Video
Presentation thumbnail
Relation of gut microbiota-dependent TMAO with aortic atherosclerosis: prognostic implication for patients with stroke
Doctor A. Haghikia (Bochum, DE)
Abstract Slides Video
Presentation thumbnail
Evidence-based medicine: challenges in implementation of new prognostic tools.
Professor M. Piepoli (San Donato Milanese, IT)
Slides Video

Access the full session

Session thumbnail
Integration of old and new prognostic biomarkers in patients with cardiovascular disease

The Event

Event poster

ESC Congress 2017

29 August 2017 14:36 CET
You may be interested in
thumbnail
Congress Presentation
Serum amyloid A-low-density-lipoprotein complex and cause-specific mortality in patients with suspected or known coronary artery disease: The ANOX Study
1 September 2024
thumbnail
Congress Presentation
The CRP/albumin ratio: a novel predictor of in-stent restenosis after carotid artery stenting
28 August 2020
thumbnail
Congress Presentation
NEU1 increases monocyte and macrophage-mediated inflammation and may act as a potential modulator of atherosclerosis
21 April 2018
thumbnail
Congress Presentation
Carotid ultrasonography improves residual risk stratification in guidelines-defined high cardiovascular risk patients
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources